GTBP Valuation

GT Biopharma Inc

Add to Watchlist

Advanced Chart

0.623

-0.004(-0.638%)1D

GTBP Relative Valuation

GTBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GTBP is overvalued; if below, it's undervalued.

Historical Valuation

GT Biopharma Inc (GTBP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.63 is considered Fairly compared with the five-year average of -3.33. The fair price of GT Biopharma Inc (GTBP) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.63

Fair

-0.65

Trailing

Forward

0.00

EV/EBITDA

GT Biopharma Inc. (GTBP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.16

EV/EBIT

GT Biopharma Inc. (GTBP) has a current EV/EBIT of 0.16. The 5-year average EV/EBIT is -1.75. The thresholds are as follows: Strongly Undervalued below -8.05, Undervalued between -8.05 and -4.90, Fairly Valued between 1.40 and -4.90, Overvalued between 1.40 and 4.55, and Strongly Overvalued above 4.55. The current Forward EV/EBIT of 0.16 falls within the Historic Trend Line -Fairly Valued range.

0.63

GT Biopharma Inc. (GTBP) has a current PS of 0.63. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below -0.08, Undervalued between -0.08 and -0.04, Fairly Valued between 0.04 and -0.04, Overvalued between 0.04 and 0.08, and Strongly Overvalued above 0.08. The current Forward PS of 0.63 falls within the Strongly Overvalued range.

0.00

P/OCF

GT Biopharma Inc. (GTBP) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.76. The thresholds are as follows: Strongly Undervalued below -9.26, Undervalued between -9.26 and -5.51, Fairly Valued between 1.99 and -5.51, Overvalued between 1.99 and 5.74, and Strongly Overvalued above 5.74. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

GT Biopharma Inc. (GTBP) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.50. The thresholds are as follows: Strongly Undervalued below -6.38, Undervalued between -6.38 and -3.94, Fairly Valued between 0.93 and -3.94, Overvalued between 0.93 and 3.37, and Strongly Overvalued above 3.37. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

GT Biopharma Inc (GTBP) has a current Price-to-Book (P/B) ratio of 0.72. Compared to its 3-year average P/B ratio of 0.64 , the current P/B ratio is approximately 11.49% higher. Relative to its 5-year average P/B ratio of 2.32, the current P/B ratio is about -69.09% higher. GT Biopharma Inc (GTBP) has a Forward Free Cash Flow (FCF) yield of approximately -467.04%. Compared to its 3-year average FCF yield of -163.67%, the current FCF yield is approximately 185.35% lower. Relative to its 5-year average FCF yield of -103.48% , the current FCF yield is about 351.33% lower.

0.72

P/B

Median3y

0.64

Median5y

2.32

-467.04

FCF Yield

Median3y

-163.67

Median5y

-103.48

Competitors Valuation Multiple

The average P/S ratio for GTBP's competitors is 3.38, providing a benchmark for relative valuation. GT Biopharma Inc Corp (GTBP) exhibits a P/S ratio of 0.63, which is -81.42% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Quoin Pharmaceuticals Ltd

11.30

6.23M

SNOA.O

Sonoma Pharmaceuticals Inc

NovaBay Pharmaceuticals Inc

Matinas BioPharma Holdings Inc

1.38

7.44M

CYCN.O

Cyclerion Therapeutics Inc

1.86

6.21M

Performance Decomposition

Market capitalization of GTBP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of GTBP in the past 1 year is driven by Unknown.